NGEN

NervGen Pharma Corp.

NGEN.US nervgen.com + Research + Basket
ISIN CA64082X2032
Employees 9
Phone 778 731 1711
Fiscal year end December
IPO Jan 08, 2026
Address 112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4
1.48
+0.00 (+0.01%)
USD · NASDAQ
52-week range
1.37
6.30
Trading at 2% of the 52-week range
Market Cap
159.13M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.31
Div. Yield
N/A
% Institutions
11.23%
% Insiders
15.61%

1 Year

-46.0%

3 Year

+5.7%

10 Year

+13.8%
Description

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Actions

Add an action for NGEN.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Adam H. Rogers M.D. President, CEO & Chairman NA
Dr. Harold Martin Punnett D.M.D. Co-Founder & Independent Director NA
Dr. Randall E. Kaye M.D. Chief Medical Advisor & Director 1962
Dr. Keith A. Vendola M.B.A., M.D. Chief Financial Officer 1972
Dr. Charles V. Olson D.Sc. Senior Vice President of Technical Operations 1957
Ms. Shamim Ruff M.S. Chief Regulatory Affairs Officer 1960
Ms. Christine McSherry Senior Vice President of Patient Advocacy & Clinical Affairs NA
Ms. Marissa Volpe SVP of Clinical Development NA

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Empery Asset Management, LP 4.00M Jun 30, 2026 3.72% $9.53 0.00%
Rock Springs Capital Management LP 1.21M Jun 30, 2026 1.12% $0.12 0.00%
Dafna Capital Management LLC 1.05M Jun 30, 2026 0.98% $0.41 0.00%
Ghisallo Capital Management LLC 1.00M Jun 30, 2026 0.93% $0.04 0.00%
Armistice Capital, LLC 678.00K Jun 30, 2026 0.63% $0.02 0.00%
LMR Partners LLP 600.00K Jun 30, 2026 0.56% $0.00 0.00%
Marshall Wace Asset Management Ltd 435.96K Jun 30, 2026 0.41% $0.00 117.59%
UBS Group AG 379.73K Jun 30, 2026 0.35% $0.00 517.27%
Stonepine Capital Management Llc 271.68K Jun 30, 2026 0.25% $0.32 0.00%
Jane Street Group LLC 270.75K Jun 30, 2026 0.25% $0.00 0.00%
Woodline Partners LP 250.50K Jun 30, 2026 0.23% $0.00 0.00%
PFG Investments, LLC 217.50K Jun 30, 2026 0.20% $0.02 8.21%
Bank of America Corp 186.20K Jun 30, 2026 0.17% $0.00 -7.20%
Royal Bank of Canada 176.08K Jun 30, 2026 0.16% $0.00 2.39%
Quadrature Capital Limited 134.52K Jun 30, 2026 0.13% $0.00 0.00%
Bank of Montreal 78.39K Jun 30, 2026 0.07% $0.00 24.63%
BMO Capital Markets Corp. 78.39K Jun 30, 2026 0.07% $0.00 24.63%
Integrated Wealth Concepts LLC 74.22K Jun 30, 2026 0.07% $0.00 -14.51%
CapTrust Financial Advisors 64.42K Jun 30, 2026 0.06% $0.00 3.30%
Geode Capital Management, LLC 58.04K Jun 30, 2026 0.05% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Nasdaq Composite Index 67.45K 0.06% ▲ 0.00% Aug 31, 2026
2 State Street® SPDR® S&P® Intl Sm Cp ETF 61.30K 0.06% ▲ 0.00% Sep 30, 2026
3 iShares Neuroscience and Healthcare ETF 8.26K 0.01% ▲ 0.00% Sep 30, 2026

Financial Highlights

▼
Market Cap: $159.13M
EBITDA: $-32.54M
Book Value: $0.31
Earnings/Share: $-0.57
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -38.04%
ROE (TTM): -96.84%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $136.92M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 107.52M
Shares Float: 95.30M
% Insiders: 15.61%
% Institutions: 11.23%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-11.17M
R&D
adjust
$-13.91M
Operating Income
subtotal
$-25.08M
Other / Non-Operating Items
adjust
$-19.04M
Net Income
subtotal
$-44.12M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NGEN.US!